Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224
Guggenheim analyst Delma Caiati maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $207 to $224.
Share
Why It Matters
A big investment expert thinks Neurocrine is worth more money now. This suggests the company looks healthier and more promising than before.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.